ATE280588T1 - Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren - Google Patents

Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren

Info

Publication number
ATE280588T1
ATE280588T1 AT99939127T AT99939127T ATE280588T1 AT E280588 T1 ATE280588 T1 AT E280588T1 AT 99939127 T AT99939127 T AT 99939127T AT 99939127 T AT99939127 T AT 99939127T AT E280588 T1 ATE280588 T1 AT E280588T1
Authority
AT
Austria
Prior art keywords
dextran
pharmaceutical compositions
related methods
leptin conjugates
leptin
Prior art date
Application number
AT99939127T
Other languages
English (en)
Inventor
David C Litzinger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE280588T1 publication Critical patent/ATE280588T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT99939127T 1998-08-10 1999-08-10 Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren ATE280588T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9619498P 1998-08-10 1998-08-10
US37068499A 1999-08-09 1999-08-09
PCT/US1999/018129 WO2000009165A1 (en) 1998-08-10 1999-08-10 Dextran-leptin conjugates, pharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
ATE280588T1 true ATE280588T1 (de) 2004-11-15

Family

ID=26791397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99939127T ATE280588T1 (de) 1998-08-10 1999-08-10 Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren

Country Status (9)

Country Link
EP (1) EP1107793B1 (de)
JP (1) JP4199421B2 (de)
AT (1) ATE280588T1 (de)
AU (1) AU5347099A (de)
CA (1) CA2337667C (de)
DE (1) DE69921486T2 (de)
ES (1) ES2228082T3 (de)
PT (1) PT1107793E (de)
WO (1) WO2000009165A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ATE323766T1 (de) * 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
EP1744786A2 (de) * 2004-03-23 2007-01-24 Amgen Inc. Chemisch modifizierte proteinzusamensetzungen un verfahren
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
WO2009143380A2 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
AU2009313562B2 (en) 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006816A1 (en) * 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997038014A1 (en) * 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods

Also Published As

Publication number Publication date
CA2337667A1 (en) 2000-02-24
EP1107793A1 (de) 2001-06-20
EP1107793B1 (de) 2004-10-27
DE69921486D1 (de) 2004-12-02
CA2337667C (en) 2008-04-29
JP2002522512A (ja) 2002-07-23
AU5347099A (en) 2000-03-06
WO2000009165A1 (en) 2000-02-24
ES2228082T3 (es) 2005-04-01
JP4199421B2 (ja) 2008-12-17
PT1107793E (pt) 2005-02-28
DE69921486T2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
DK1157037T3 (da) GCSF-konjugater
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
NO20002785L (no) Adamantanderivater
NO20002786L (no) Adamantanderivater
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
TR200100054T2 (tr) Paroksetin metansülfonat
ATE231872T1 (de) Thiazolopyrimidinderivate
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
TR200103827T2 (tr) Farmakolojik kompleks
SE9803107D0 (sv) Novel Compunds
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
SE9803277D0 (sv) Novel compounds
IT1311913B1 (it) Impiego di 6-metilmercaptopurina riboside in composizionioftalmologiche.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107793

Country of ref document: EP